A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
Open accessAbstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective and safe vaccines. Similar to SARS-CoV, SARS-CoV-2 recognizes angiotensin-converting enzyme 2 (ACE2) as receptor for host cell entry. 1 , 2 SARS-CoV-2 spike (S) protein consists of S1, including receptor-binding domain (RBD), and S2 subunits. 3 , 4 We previously demonstrated that RBDs of SARS-CoV and MERS-CoV serve as important targets for the development of effective vaccines. 5 , 6
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The RBD can induce strong humoral and cellular immune responses when used as an antigen in various SARS-CoV and MERS-CoV studies.
“the RBD can induce strong humoral and cellular immune responses when used as an antigen in various SARS-CoV and MERS-CoV studies),8, 9, 10”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [9]
The introduction (page not supplied) says SARS-CoV and MERS-CoV RBDs were previously shown to be targets for effective vaccines. The paper reports humoral and T-cell responses to a SARS-CoV-2 RBD vaccine in mice, but does not state that the earlier SARS-CoV and MERS-CoV studies demonstrated both strong humoral and cellular responses. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThe receptor binding domain (RBD) of SARS-CoV-2 spike protein had been identified to play a key role in helping coronaviruses to enter human cells.
“the receptor binding domain (RBD) of SARS-CoV-2 spike protein had been identified to play a key role in helping coronaviruses to enter human cells”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [9]
Human data corroborate reports that demonstrate the induction of potent germinal centre responses by SARS-CoV-2 mRNA-based vaccines in mice.
“Our data in humans corroborate reports that demonstrate the induction of potent germinal centre responses by SARS-CoV-2 mRNA-based vaccines in mice22,23.”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · see citing works
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · see citing works
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · see citing works
Self-citationThe spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,649 · see citing works
Self-citationSARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works
Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0305-x · Cited by 1,340 · see citing works
Self-citationDNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works
Germinal-Center Organization and Cellular Dynamics
Allen, C. D. C., Okada, T., & Cyster, J. G. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.009 · Cited by 986 · see citing works
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · see citing works
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 424 · see citing works
Self-citationChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · doi:10.1101/2020.05.13.093195 · Cited by 246 · see citing works
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessPreprint
Corbett, K. S., Edwards, D. K., Leist, S. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.11.145920 · Cited by 143 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831 · see citing works
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 801 · see citing works
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636 · see citing works
Self-citationLipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 638 · see citing works
COVID-19 vaccine development: milestones, lessons and prospects
Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 448 · see citing works
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422 · see citing works
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Bettini, E., & Locci, M. (2021) · Vaccines · doi:10.3390/vaccines9020147 · Cited by 283 · see citing works
Circular RNA vaccine in disease prevention and treatment
Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 273 · see citing works
Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265 · see citing works
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 242 · see citing works
COVID-19: Coronavirus Vaccine Development Updates
Zhao, J., Zhao, S., Ou, J., Zhang, J., Lan, W., Guan, W., Wu, X., Yan, Y., Zhao, W., Wu, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.602256 · Cited by 225 · see citing works
Liu, Z., Xu, W., Xia, S., Gu, C., Wang, X., Wang, Q., Zhou, J., Wu, Y., Cai, X., Qu, D., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00402-5 · Cited by 192 · see citing works
Self-citationPowell, A. E., Zhang, K., Sanyal, M., Tang, S., Weidenbacher, P. A. B., Li, S., Pham, T. D., Pak, J. E., Chiu, W., & Kim, P. S. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01405 · Cited by 174 · see citing works
Learning from the past: development of safe and effective COVID-19 vaccines
Su, S., Du, L., & Jiang, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00462-y · Cited by 164 · see citing works
Self-citationWang, Y., Tiruthani, K., Li, S., Hu, M., Zhong, G., Tang, Y., Roy, S., Zhang, L., Tan, J. H., Liao, C., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007603 · Cited by 144 · see citing works
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 135 · see citing works
Next-Generation TB Vaccines: Progress, Challenges, and Prospects
Li, Z., Ye, Z., Li, L., Yang, L., & Gong, W. (2023) · Vaccines · doi:10.3390/vaccines11081304 · Cited by 121 · see citing works
Wang, Y., Xie, Y., Luo, J., Guo, M., Hu, X., Chen, X., Chen, Z., Lu, X., Mao, L., Zhang, K., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101139 · Cited by 107 · see citing works
Elia, U., Ramishetti, S., Rosenfeld, R., Dammes, N., Bar‐Haim, E., Naidu, G. S., Makdasi, E., Yahalom-Ronen, Y., Tamir, H., Paran, N., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10180 · Cited by 100 · see citing works
Wang, S., Li, W., Wang, Z., Yang, W., Li, E., Xia, X., Yan, F., & Chiu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01917-x · Cited by 117 · see citing works
Manikkath, J., & Subramony, J. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113997 · Cited by 98 · see citing works
Sun, W., He, L., Zhang, H., Tian, X., Bai, Z., Sun, L., Yang, L., Jia, X., Bi, Y., Luo, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00750-w · Cited by 83 · see citing works
Chen, G.-L., Li, X.-F., Dai, X.-H., Li, N., Cheng, M.-L., Huang, Z., Shen, J., Ge, Y.-H., Shen, Z.-W., Deng, Y.-Q., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00280-9 · Cited by 82 · see citing works
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21037-2 · Cited by 76 · see citing works
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 74 · see citing works
Microarray patches enable the development of skin-targeted vaccines against COVID-19
Korkmaz, E., Balmert, S. C., Sumpter, T. L., Carey, C. D., Erdös, G., & Falo, L. D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.022 · Cited by 59 · see citing works
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
Dickey, T. H., Tang, W. K., Butler, B., Ouahes, T., Orr-Gonzalez, S., Salinas, N. D., Lambert, L., & Tolia, N. H. (2022) · Science Advances · doi:10.1126/sciadv.abq8276 · Cited by 60 · see citing works
Kang, Y., Sun, C., Sun, J., Xie, C., Zhuang, Z., Xu, H.-Q., Liu, Z., Liu, Y., Peng, S., Yuan, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30222-w · Cited by 56 · see citing works
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49 · see citing works
Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2
Kamat, S., Kumari, M., & Jayabaskaran, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.046 · Cited by 51 · see citing works
Jafari, A., Pouya, F. D., Niknam, Z., Abdollahpour‐Alitappeh, M., Rezaei–Tavirani, M., & Rasmi, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07132-7 · Cited by 49 · see citing works
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
Cai, X., Li, J. J., Liu, T., Brian, O., & Li, J. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab027 · Cited by 47 · see citing works
Oktay, E., Alem, F., Hernandez, K. R., Girgis, M. J., Green, C. M., Mathur, D., Medintz, I. L., Narayanan, A., & Veneziano, R. (2023) · Communications Biology · doi:10.1038/s42003-023-04689-2 · Cited by 45 · see citing works
Park, K. S., Bazzill, J. D., Son, S., Nam, J., Shin, S. W., Ochyl, L. J., Stuckey, J. A., Meagher, J. L., Chang, L. C., Song, J. W., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.031 · Cited by 44 · see citing works
Hardy, E., & Fernández-Patrón, C. (2021) · Biomolecules · doi:10.3390/biom11030390 · Cited by 44 · see citing works
Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells
Aditham, A. J., Shi, H., Guo, J., Zeng, H., Zhou, Y., Wade, S. D., Huang, J., Jia Liu, B., & Wang, X. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00569 · Cited by 45 · see citing works
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 44 · see citing works
Dendritic Cell‐Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs
Cao, Y., Long, J., Sun, H., Miao, Y., Sang, Y., Lü, H., Yu, C., Zhang, Z., Wang, L., Yang, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202302423 · Cited by 42 · see citing works
Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
Goupil, R., Benlarbi, M., Beaubien-Souligny, W., Nadeau-Fredette, A.-C., Chatterjee, D., Goyette, G., Gunaratnam, L., Lamarche, C., Tom, A., Finzi, A., et al. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210673 · Cited by 39 · see citing works
Biomarkers of ageing and frailty may predict COVID-19 severity
Wanhella, K. J., & Fernández-Patrón, C. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101513 · Cited by 40 · see citing works
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Du, L., Yang, Y., Zhang, X., & Li, F. (2021) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 41 · see citing works
Self-citationAdvanced Materials for SARS‐CoV‐2 Vaccines
Mabrouk, M. T., Huang, W., Martínez‐Sobrido, L., & Lovell, J. F. (2021) · Advanced Materials · doi:10.1002/adma.202107781 · Cited by 38 · see citing works
Patel, N., Davis, Z., Hofmann, C., Vlasak, J., Loughney, J. W., DePhillips, P. A., & Mukherjee, M. (2023) · Vaccines · doi:10.3390/vaccines11071224 · Cited by 40 · see citing works
Li, M., Li, S., Huang, Y., Chen, H., Zhang, S., Zhang, Z., Wu, W., Zeng, X., Zhou, B., & Li, B. (2021) · Advanced Materials · doi:10.1002/adma.202101707 · Cited by 39 · see citing works
Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
Karpenko, L., Rudometov, A. P., Sharabrin, S. V., Shcherbakov, D., Borgoyakova, M. B., Bazhan, S., Volosnikova, E., Rudometova, N., Orlova, L. A., Pyshnaya, I., et al. (2021) · Vaccines · doi:10.3390/vaccines9020076 · Cited by 37 · see citing works
Immune Response to SARS-CoV-2 Vaccines
Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 35 · see citing works
Cao, H., Ma, R., Chu, S., Xi, J., Yu, L., & Guo, R. H. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.03.029 · Cited by 37 · see citing works
Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2
Nguyen, K., Chakraborty, S., Mansbach, R. A., Korber, B., & Gnanakaran, S. (2021) · Viruses · doi:10.3390/v13050927 · Cited by 36 · see citing works
Advances in mRNA and other vaccines against MERS-CoV
Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 32 · see citing works
Self-citationAnti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment
Souri, M., Chiani, M., Farhangi, A. A., Mehrabi, M. R., Nourouzian, D., Raahemifar, K., & Soltani, M. (2022) · Nanomaterials · doi:10.3390/nano12050783 · Cited by 32 · see citing works
Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant
Tai, W.-B., Chai, B.-J., Feng, S.-J., Zhuang, X., Ma, J., Pang, M., Pan, L., Yang, Z., Tian, M.-Y., & Cheng, G. (2022) · bioRxiv · doi:10.1038/s41392-022-01041-8 · Cited by 32 · see citing works
Self-citationKumar, M., Kumari, N., Thakur, N., Bhatia, S. K., Saratale, G. D., Ghodake, G. S., Mistry, B. M., Alavilli, H., Kishor, D. S., Du, X., et al. (2021) · Plants · doi:10.3390/plants10061213 · Cited by 31 · see citing works
Zhang, K., Wang, Z., Liu, H., Perea‐López, N., Ranasinghe, J. C., Bepete, G., Minns, A. M., Rossi, R. M., Lindner, S. E., Huang, X., et al. (2022) · ACS Photonics · doi:10.1021/acsphotonics.2c00456 · Cited by 33 · see citing works
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179 · see citing works
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Guan, X., Yang, Y., & Du, L. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2211153 · Cited by 28 · see citing works
Self-citationCao, M., Su, X., & Jiang, S. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.12.010 · Cited by 27 · see citing works
Self-citationSharifi, E., Yousefiasl, S., Trovato, M., Sartorius, R., Esmaeili, Y., Goodarzi, H., Ghomi, M., Bigham, A., Moghaddam, F. D., Heidarifard, M., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01938-8 · Cited by 29 · see citing works
Ortega-Rivera, O. A., Shukla, S., Shin, M. D., Chen, A., Beiss, V., Moreno‐Gonzalez, M. A., Zheng, Y., Clark, A. E., Carlin, A. F., Pokorski, J. K., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00410 · Cited by 26 · see citing works
Shi, J., Zheng, J., Tai, W.-B., Verma, A. K., Zhang, X., Geng, Q., Wang, G., Guan, X., Malisheni, M., Odle, A. E., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00118-22 · Cited by 22 · see citing works
Self-citationUncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
Li, T.-Y., Cai, H., Zhao, Y.-P., Li, Y., Lai, Y., Yao, H., Liu, L. D., Sun, Z., van Vlissingen, M. F., Kuiken, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114544 · Cited by 23 · see citing works
Self-citationRational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid
Li, L., Long, J., Sang, Y., Wang, X., Zhou, X., Pan, Y., Cao, Y., Huang, H., Yang, Z., Yang, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.023 · Cited by 24 · see citing works
Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy
Syed, S. N., & Brüne, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094493 · Cited by 24 · see citing works
Sreter, J. A., Foxall, T. L., & Varga, K. (2022) · Biomolecules · doi:10.3390/biom12050669 · Cited by 23 · see citing works
Machine Learning Interpretation of Optical Spectroscopy Using Peak-Sensitive Logistic Regression
Wang, Z., Ranasinghe, J. C., Wu, W., Chan, D. C. Y., Gomm, A., Tanzi, R. E., Zhang, C. M., Zhang, N., Allen, G. I., & Huang, S. (2025) · ACS Nano · doi:10.1021/acsnano.4c16037 · Cited by 22 · see citing works
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infectionPreprint
Moore, A., Dora, E. G., Peinovich, N., Tucker, K., Lin, K., Cortese, M., & Tucker, S. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.04.283853 · Cited by 22 · see citing works
Jeong, H., Choi, Y.-M., Seo, H., & Kim, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637654 · Cited by 21 · see citing works
Yang, Z., Wu, D., Lu, S., Qiu, Y., Hua, Z., Tan, F., Zhang, C., Zhang, L., Zhang, D., Zhou, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117089119 · Cited by 21 · see citing works
Tai, W., Zheng, J. H., Zhang, X., Shi, J., Wang, G., Guan, X., Zhu, J., Perlman, S. M., & Du, L. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199156 · Cited by 21 · see citing works
Self-citationEffect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review
Tofarides, A. G., Christaki, E., Milionis, H. J., & Nikolopoulos, G. K. (2022) · Life · doi:10.3390/life12122057 · Cited by 19 · see citing works
Shi, J., Wang, G., Zheng, J. H., Verma, A. K., Guan, X., Malisheni, M. M., Geng, Q., Li, F., Perlman, S. M., & Du, L. (2022) · npj Vaccines · doi:10.1038/s41541-022-00580-z · Cited by 18 · see citing works
Self-citationShi, J., Zheng, J. H., Zhang, X., Tai, W., Odle, A. E., Perlman, S. M., & Du, L. (2022) · Translational research · doi:10.1016/j.trsl.2022.04.007 · Cited by 18 · see citing works
Self-citationCircRNA: Unlocking new frontiers in therapeutic and vaccine development
Bahrulolum, H., Rouzbahani, F. N., Hoseini, Z. S., Chaharmahali, M., & Hosseini, S. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.038 · Cited by 18 · see citing works
SARS-CoV-2 virus: Vaccines in development
Huang, Q.-R., & Yan, J.-H. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.009 · Cited by 17 · see citing works
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge
Wang, G., Verma, A. K., Guan, X., Bu, F., Odle, A. E., Li, F., Liu, B., Perlman, S. M., & Du, L. (2024) · Journal of Virology · doi:10.1128/jvi.00376-24 · Cited by 17 · see citing works
Self-citationDistinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
Tian, S., Ji, K., Wang, M., Wang, F., Wang, H., Huang, W., Huang, Q., & Yan, J. (2021) · Cell Discovery · doi:10.1038/s41421-021-00331-9 · Cited by 17 · see citing works
Maghsood, F., Amiri, M. M., Zarnani, A., Salimi, V., Kardar, G. A., Khoshnoodi, J., Mobini, M., Zare, H. A., Ghaderi, A. A., Jeddi‐Tehrani, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.973036 · Cited by 17 · see citing works
Guirakhoo, F., Kuo, L., Peng, J., Huang, J.-H., Kuo, B.-S., Lin, F., Liu, Y.-J., Liu, Z., Wu, G., Ding, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.30.399154 · Cited by 16 · see citing works
Qin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16 · see citing works
Su, S., Wang, Q., & Jiang, S. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.284 · Cited by 15 · see citing works
Self-citationZhang, H., Xie, R., Zhang, H., Sun, R., Li, S., Xia, C., Li, Z., Zhang, L., Guo, Y., & Huang, J. (2023) · Poultry Science · doi:10.1016/j.psj.2023.102662 · Cited by 14 · see citing works
Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domainPreprint
Kobiyama, K., Imai, M., Jounai, N., Nakayama, M., Hioki, K., Iwatsuki‐Horimoto, K., Yamayoshi, S., Tsuchida, J., Niwa, T., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433852 · Cited by 15 · see citing works
Zhang, M., Singh, N., Ehmann, M. E., Zheng, L., & Zhao, H. (2023) · iScience · doi:10.1016/j.isci.2023.107739 · Cited by 15 · see citing works
Wang, G., Shi, J., Verma, A. K., Guan, X., Perlman, S. M., & Du, L. (2022) · iScience · doi:10.1016/j.isci.2022.105690 · Cited by 14 · see citing works
Self-citationUraki, R., Imai, M., Ito, M., Yamayoshi, S., Kiso, M., Jounai, N., Miyaji, K., Iwatsuki‐Horimoto, K., Takeshita, F., & Kawaoka, Y. (2024) · npj Vaccines · doi:10.1038/s41541-023-00800-0 · Cited by 13 · see citing works
A T cell–based SARS-CoV-2 spike protein vaccine provides protection without antibodies
Shi, J., Zheng, J. H., Zhang, X., Tai, W., Compas, R., Deno, J., Jachym, N., Verma, A. K., Wang, G., Guan, X., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.155789 · Cited by 13 · see citing works
Self-citationA PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice
Li, M., Huang, Y., Wu, J., Li, S., Mei, M., Chen, H., Wang, N., Wu, W., Zhou, B., Tan, X., et al. (2022) · Materials Horizons · doi:10.1039/d2mh01260j · Cited by 13 · see citing works
Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2
Shi, J., Zhao, Y., Peng, M., Zhu, S., Wu, Y., Ji, R., & Shen, C. (2023) · Vaccines · doi:10.3390/vaccines11040713 · Cited by 12 · see citing works
Self-citationDevelopment of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice
Qin, X., Li, S., Li, X., Pei, D., Liu, Y., Ding, Y., Liu, L., Bi, H., Shi, X., Guo, Y., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.802147 · Cited by 12 · see citing works
Huang, Y., Shi, H., Forgacs, D., & Ross, T. M. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.12.084 · Cited by 12 · see citing works
Qu, X., Jia, Y., Jia, N., Fan, H., Zheng, A., Xia, L., Wang, Z., Tian, D., Niu, S., Hu, Y., et al. (2023) · hLife · doi:10.1016/j.hlife.2023.07.001 · Cited by 11 · see citing works
Srivastava, V., Niu, L., Phadke, K. S., Bellaire, B. H., & Cho, M. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637982 · Cited by 11 · see citing works
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV
Wang, G., Verma, A. K., Shi, J., Guan, X., Meyerholz, D. K., Bu, F., Wen, W., Liu, B., Li, F., Perlman, S. M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00922-z · Cited by 10 · see citing works
Self-citationRecurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response
Verma, A., Manojkumar, A., Dhasmana, A., Tripathi, M. K., Jaggi, M., Chauhan, S. C., Chauhan, D. S., & Yallapu, M. M. (2024) · Nanotheranostics · doi:10.7150/ntno.91910 · Cited by 11 · see citing works
Tien, N., Chang, Y.-C., Chen, P., Lin, H., Chang, S., Lan, J., Hsueh, P., Chang, C., & Chen, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040911 · Cited by 10 · see citing works
A review of COVID‐19 vaccines and major considerations for diabetic patients
Soltani, S., Zandi, M., Aghbash, P. S., Rezaei, M., Mohammadzadeh, N., Afsharifar, A., & Poortahmasebi, V. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2076 · Cited by 8 · see citing works
Adjuvants in cutaneous vaccination: A comprehensive analysis
Oladejo, M., Tijani, A. O., Puri, A., & Chablani, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.045 · Cited by 9 · see citing works
Stepanova, E., Николаевна, И.-С. И., Mezhenskaya, D. А., Niskanen, S., Matyushenko, V., Bazhenova, E. A., Rak, A. Y., Wong, P.-F., Игоревна, П. П., Kotomina, T. S., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02350-w · Cited by 8 · see citing works
Fan, Y., Wei, J., Wang, W., Li, C., Pan, G., Keiffer, T. R., Bao, J., & Zhou, Z. (2022) · Pathogens · doi:10.3390/pathogens11060672 · Cited by 8 · see citing works
Firmino-Cruz, L., dos-Santos, J. S., da Fonseca-Martins, A. M., Oliveira-Maciel, D., Pérez, G., Pereira, V. A. R., Dumard, C. H., Guedes-da-Silva, F. H., Santos, A. C. V., Alvim, R. G. F., et al. (2022) · Vaccines · doi:10.3390/vaccines10081305 · Cited by 8 · see citing works
- Authors
- Tai, W., Zhang, X., Drelich, A., Shi, J., Hsu, J. C., Luchsinger, L., Hillyer, C. D., Tseng, C.-T. K., Jiang, S., & Du, L.
- Affiliations
- New York Blood Center (US)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Jiang, Shibo
- Du, Lanying
- ORCID
- Venue
- Cell Research
- Published
- 2020-08-05
- Volume
- 30
- Issue
- 10
- Pages
- 932-935
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- PMC
- PMC7403570
- OpenAlex
- W3046985131
- Cited by
- 151
- References
- 12
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 20 · 2022: 41 · 2021: 48 · 2020: 11
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cell Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (R01AI137472, R01AI139092)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI137472, R01AI139092, R01AI157975)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, COVID-19 pandemic, mRNA vaccines, receptor binding domain, spike protein, ACE2 receptor, vaccine design, coronavirus vaccines
- MeSH terms
- Protein Domains, Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Animals, Cell Line, Humans, Immunization, Mice, Inbred BALB C, Pneumonia, Viral, RNA, Messenger, Viral Vaccines, Gene Expression, Coronavirus Infections, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
